Clinical trials: in Singapore
Triple-Negative Breast Cancer
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with…
- Trial name
- NCT06393374
- Testing
- Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
- Where
- 314 sites in United States, Argentina and 29 more
- Volunteers
- 1,530 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study…
- Trial name
- B-Sure (NCT04954859)
- Testing
- Bepirovirsen
- Where
- 161 sites in United States, Argentina and 27 more
- Volunteers
- 366 people
- Sponsor
- GlaxoSmithKline
Melasma, Melasma (Facial Melasma)
To Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of Melasma
The purpose of this study is to find out whether a new combination cream containing eflornithine, hydroquinone, and fluocinolone works better and causes fewer side effects than Tri-Luma® (tretinoin, hydroquinone, and…
- Trial name
- NCT07876323
- Testing
- Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% cream, Tretinoin 0.05% + hydroquinone 4% + fluocinolone 0.01% cream
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National Skin Centre
Endometrial Neoplasms
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed…
- Trial name
- DUO-E (NCT04269200)
- Testing
- olaparib, durvalumab, Carboplatin
- Where
- 201 sites in United States, Australia and 20 more
- Volunteers
- 805 people
- Sponsor
- AstraZeneca
Breast Neoplasms
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced…
- Trial name
- NCT02297438
- Testing
- Palbociclib, Letrozole
- Where
- 54 sites in China, Hong Kong and 3 more
- Volunteers
- 340 people
- Sponsor
- Pfizer
Skin Laxity
Effectiveness of Sequential Monopolar and Bipolar Radiofrequency Device for Facial Rejuvenation in Female Participants
The purpose of this study is to find out whether a single treatment with the DENSITY radiofrequency device improves facial skin laxity (sagging), skin texture, and pore appearance in adult women, and whether the treatment is safe…
- Trial name
- NCT07919990
- Testing
- DENSITY sequential monopolar and bipolar radiofrequency device
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- Cutis Medical Laser Clinics Pte Ltd
Hyperaldosteronism; Primary, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging.
- Trial name
- NCT07297745
- Testing
- Hybrid hormones
- Where
- 6 sites in Singapore
- Volunteers
- 120 people
- Sponsor
- Changi General Hospital
Chronic Kidney Disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Trial name
- NCT07107945
- Testing
- Empagliflozin
- Where
- 93 sites in United States, Argentina and 16 more
- Volunteers
- 135 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07361497
- Testing
- Pumitamig, Durvalumab
- Where
- 259 sites in United States, Argentina and 30 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
Neuromuscular Disease, Neuromuscular Diseases (NMD)
A Phase 3 Study of NTLA-2001 in ATTRv-PN
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
- Conditions
- Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary
- Trial name
- NCT06672237
- Testing
- nexiguran ziclumeran
- Where
- 14 sites in Argentina, Brazil and 4 more
- Volunteers
- 67 people
- Sponsor
- Intellia Therapeutics
Aging
Superficial MFU-V and Diluted Calcium Hydroxyapatite for the Improvement of Lower Face Skin Quality and Wrinkles
This single-center pilot study evaluated whether one treatment session combining superficial microfocused ultrasound with visualization (MFU-V, Ultherapy, 1.5 mm transducer) and diluted calcium hydroxylapatite (CaHA, Radiesse…
- Trial name
- NCT05469516
- Testing
- Ulthera System [Ulthera, Inc.], Merz Radiesse Injectable Implant
- Where
- Singapore
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Cutis Medical Laser Clinics Pte Ltd
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with…
- Conditions
- PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
- Trial name
- ReDiscover-2 (NCT06982521)
- Testing
- Zovegalisib, Capivasertib, Fulvestrant
- Where
- 254 sites in United States, Argentina and 25 more
- Volunteers
- 540 people
- Sponsor
- Relay Therapeutics, Inc.
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS…
- Trial name
- Krascendo 2 (NCT06793215)
- Testing
- Divarasib, Pembrolizumab, Pemetrexed
- Where
- 299 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Essential Thrombocythemia
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
- Trial name
- EXCALIBUR-ET2 (NCT07623200)
- Testing
- INCA033989, Best Available Treatment
- Where
- 192 sites in United States, Australia and 20 more
- Volunteers
- 426 people
- Sponsor
- Incyte Corporation
EGFR-mutant Non-small Cell Lung Cancer
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor…
- Trial name
- NCT03333343
- Testing
- EGF816, trametinib, ribociclib
- Where
- 11 sites in Canada, Germany and 4 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Paroxysmal Nocturnal Hemoglobinuria
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- ACCESS-EXT (NCT05744921)
- Testing
- Pozelimab, Cemdisiran
- Where
- 50 sites in Brazil, Canada and 19 more
- Volunteers
- 202 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Disease
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation).
- Trial name
- NCT06963827
- Testing
- Mezagitamab
- Where
- 186 sites in United States, Argentina and 24 more
- Volunteers
- 347 people
- Sponsor
- Takeda
Locally Advanced Solid Tumors, Recurrent Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802…
- Conditions
- Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
- Trial name
- NCT06031441
- Testing
- RO7566802, Atezolizumab
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.